Drug Pricing & Negotiation
Expert articles and analysis related to drug pricing & negotiation.
AI Summary — Last 7 Days
Over the past week, the Trump administration's push for drug pricing reform has become more pronounced, particularly through the ongoing implications of the most-favored nation (MFN) deals with pharmaceutical companies, which are set to expire for some manufacturers. This aligns with President Trump's strategy to compel European countries to shoulder a greater cost of pharmaceuticals, thereby potentially lowering U.S. drug prices but creating uncertainty for international stakeholders. Concurrently, state programs are facing budget constraints, leading to restricted access to essential HIV medications, highlighting the fragility of healthcare financing amidst changing policies and economic pressures, as noted in the situation surrounding the Ryan White HIV/AIDS Program.
Related Articles
Real world experience with insurers pushing back on copay cards
As reported by Kaiser Health News: The value of drugmakers’ copay cards has become more unpredictable as insurers try to restrict their use. Many insurance plans, for instance, do not count the money ...
STAT+: Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccines
A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.
STAT+: Virginia lawmakers push a new approach to a prescription drug affordability board
As states try to contain the cost of prescription drugs, Virginia lawmakers are pushing an affordability board they believe will go further than efforts in other states.
Opinion: CMS shouldn’t be paying for higher-than-necessary doses of cancer drugs
In cancer treatment, higher doses with worse side effects often don’t lead to better outcomes.
STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more
The most-favored nation drug pricing deals the Trump administration reached with 16 drugmakers end after three years in some cases, according to SEC filings
STAT+: Trump’s drive to get Europe to pay more for drugs creates uncertainty for countries, patients
President Trump's demand that wealthy countries in Europe spend more on drugs so the U.S. can pay less has introduced uncertainty across the continent.
STAT+: Minnesota report shows large hospitals continue to dominate the 340B drug discount program
Minnesota hospitals and clinics participating in a controversial U.S. drug discount program reaped at least $1.34 billion in revenue in 2024.
STAT+: Trump most-favored nation drug pricing deals end after three years for some companies
SEC filings show that, at least for some drugmakers, "most-favored nation" drug pricing deals with President Trump last three years.
As Drug Pricing Grows More Complex, Scripta Offers Comparison Tools: Eric Levin
He Needs an Expensive Drug. A Copay Card Helped — Until It Didn’t.
Diagnosed with an autoimmune disorder, a California man was prescribed a drug that costs thousands of dollars a month. He said he was reassured that the drugmaker’s copay card would cover his share, b...